Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Ambrx revenue
Ambrx's revenue is $7.4 million.
What is Ambrx's revenue?
- Ambrx's revenue growth from 2020 to 2022 is -45.86%.
- Ambrx has 80 employees, and the revenue per employee ratio is $92,525.
- Ambrx's peak quarterly revenue was $1.1M in 2023(q2).
- Ambrx peak revenue was $13.7M in 2020.
- Ambrx annual revenue for 2021 was 7.5M, -45.47% growth from 2020.
- Ambrx annual revenue for 2022 was 7.4M, -0.71% growth from 2021.
On this page
Zippi applies for you, and finds you a job.
Ambrx historical revenue
Ambrx's peak revenue was $13.7M in 2020. The peak quarterly revenue was $1.1M in 2023(q2).
Ambrx's revenue increased from $13.7m in 2020 to $7.4M currently. That's a -45.86% change in annual revenue.
Ambrx annual revenue
Ambrx annual revenue over time
| Fiscal year / year | Ambrx revenue |
|---|---|
| 2020 | $13.7M |
| 2021 | $7.5M |
| 2022 | $7.4M |
Ambrx jobs nearby
Do you work at Ambrx?
Did Ambrx meet its revenue projections?
Ambrx financial information
| CEO | Tiecheng Qiao (Alex) |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 80 |
| Date Founded | 2003 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $7.4M |
| Net Income | -$77,996,000 |
| Tax Rate | -0.0% |
| Total Assets | $146,977,000 |
| Ticker | AMAM |
Ambrx jobs you might like
Ambrx financing
Ambrx received early financing of $12.5M on 2003-09-25.
| Series | Round size | Date |
|---|---|---|
| Series A | $12.5M | 09/2003 |
| Series A | $23.4M | 03/2005 |
| Series B | $5M | 01/2006 |
| Series C | $52M | 07/2006 |
| Series D | $10M | 04/2009 |
| Series Unknown | $45M | 08/2016 |
| Private Equity | $200M | 11/2020 |
Ambrx investors
| Investors | Security type |
|---|---|
| Tavistock Group | Series A |
| 5 Am Ventures | Series A |
| Versant Ventures | Series A |
| Tavistock Group | Series A |
| 5 Am Ventures | Series A |
| Maverick Ventures | Series A |
| Versant Ventures | Series B |
| Tavistock Group | Series B |
| 5 Am Ventures | Series B |
| Aravis Ventures | Series C |
| Versant Ventures | Series C |
| Tavistock Group | Series C |
| 5 Am Ventures | Series C |
| CMEA Capital | Series C |
| Roche Venture Fund | Series C |
| Apposite Capital | Series C |
| Maverick Ventures | Series C |
| Aravis Ventures | Series D |
| M Ventures | Series D |
| Versant Ventures | Series D |
| Tavistock Group | Series D |
| 5 Am Ventures | Series D |
| CMEA Capital | Series D |
| Maverick Ventures | Series D |
| Apricot Capital | Series Unknown |
| HOPU Investment Management Company | Series Unknown |
| Northeast Securities | Series Unknown |
| Everbright | Series Unknown |
| Sinopharm Holding | Series Unknown |
| HBM Healthcare Investments AG | Private Equity |
| Invus | Private Equity |
| Suvretta Capital Management LLC | Private Equity |
| Adage Capital Management | Private Equity |
| Cormorant Asset Management | Private Equity |
| Fidelity Management & Research Co LLC | Private Equity |
| BlackRock, Inc. | Private Equity |
Ambrx competitors
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Sutro Biopharma | - | $62.0M | 160 | - |
| Sesen Bio | - | $19.6M | 35 | - |
| Sorbent Therapeutics | - | - | 31 | - |
| Zymeworks | - | $26.6M | 450 | - |
| eFFECTOR Therapeutics | - | $42.0M | 24 | - |
| GT Biopharma | - | $27,000 | 2 | - |
| Zyomyx | - | $840,000 | 5 | - |
| ZymoGenetics | - | $27.0M | 200 | - |
| Arena Pharmaceuticals | - | $54,000 | 194 | - |
| Cellerant Therapeutics | - | $3.8M | 7 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Ambrx highest paying jobs
Zippia gives an in-depth look into the details of Ambrx, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Ambrx. The employee data is based on information from people who have self-reported their past or current employments at Ambrx. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Ambrx. The data presented on this page does not represent the view of Ambrx and its employees or that of Zippia.
Ambrx may also be known as or be related to AMBRX INC, Ambrx, Ambrx Inc and Ambrx, Inc.